FORM 7

MONTHLY PROGRESS REPORT

Name of Listed Issuer: **Global Cannabis Applications Corp.** (the “**Issuer**”)

Trading Symbol: **APP**

Number of Outstanding Listed Securities: **100,619,201 (as at May 31, 2019)**

Date: **June 5, 2019**

This Monthly Progress Report must be posted before the opening of trading on the fifth trading day of each month. This report is not intended to replace the Issuer’s obligation to separately report material information forthwith upon the information becoming known to management or to post the forms required by Exchange Policies. If material information became known and was reported during the preceding month to which this report relates, this report should refer to the material information, the news release date and the posting date on the Exchange website.

This report is intended to keep investors and the market informed of the Issuer’s ongoing business and management activities that occurred during the preceding month. Do not discuss goals or future plans unless they have crystallized to the point that they are "material information" as defined in the Policies. The discussion in this report must be factual, balanced and non-promotional.

**General Instructions**

1. Prepare this Monthly Progress Report using the format set out below. The sequence of questions must not be altered nor should questions be omitted or left unanswered. The answers to the items must be in narrative form. State when the answer to any item is negative or not applicable to the Issuer. The title to each item must precede the answer.
2. The term “Issuer” includes the Issuer and any of its subsidiaries.
3. Terms used and not defined in this form are defined or interpreted in Policy 1 – Interpretation and General Provisions.

**Report on Business**

1. Provide a general overview and discussion of the development of the Issuer’s business and operations over the previous month. Where the Issuer was inactive disclose this fact.

 ***The Issuer is a global leader in designing, developing, marketing and acquiring innovative data technologies for the cannabis industry. The Citizen Green platform is the world’s first end-to-end – from patient to regulator – medical cannabis data solution. It uses six core technologies: mobile applications, artificial intelligence, regtech, smart databases, blockchain and digital reward tokens, to qualify candidates for clinical studies. These technologies facilitate the proliferation of digital conversations by like-minded people in the medical cannabis community. Managed by digital and cannabis industry experts, the Issuer is focused on viral global expansion by providing the best digital experience in the cannabis market.***

**During the month of May 2019, the Issuer continued with general and corporate operations with no changes to material activities.**

1. Provide a general overview and discussion of the activities of management.

**During the month of May 2019, management continued to support and control the Issuer’s business activities with a focus on creating broader awareness of the Issuer and continued development of product line.**

**In addition, on May 13, 2019, the Issuer announced by news release that it has signed a software licence agreement for its Citizen Green Prescriptii patient-care solution with Sequoya Cannabis Ltd., a Canadian medical cannabis distribution and cannabidiol extraction firm with operations in Poland.**

**Pursuant to the execution of the licence agreement, Global Cannabis will become a significant shareholder of Sequoya.**

**"The Sequoya-Global Cannabis partnership is the completion of our first stage of becoming vertically integrated, leveraging our Citizen Green technology and relationships in the EU and Israel to acquire interests in production, extraction and distribution. We are keen to get to work with Sequoya since they have been developing their business and relationships in Poland since legalization," said Brad Moore, chief executive officer of Global Cannabis. "Poland is an excellent example of the opportunities in the EU and the role Global Cannabis can play. EU regulatory demands for information will be powered by data from Citizen Green technology. The next step of our vertical integration strategy will be working with Israeli licensed producers who truly understand the opportunities of medical cannabis from decades of state-sponsored programs in Israel."**

**"The ability to manage cannabis prescriptions and educate the marketplace on treatments based on research is vital for pharmacies, doctors and patients. The solution offered by Global Cannabis will give Sequoya Cannabis Ltd. a competitive advantage in Poland, as we plan to offer our CBD products and the Prescriptii software as a combined offering, differentiating us from others that offer just a 'product' to a full solution. Prescriptii provides Polish pharmacies with a tool to track the prescriptions and treatments as strictly required by law. In addition, it offers market insights that will help pharmacies take advantage of this growing market for medical cannabis, which has much higher margins than non-organic medication offered by pharmaceutical companies," says Shemek Fedyczkowski, CEO of Seqouya.**

**In addition, Global Cannabis and Grand Rock Capital Inc. have signed a letter of intent to provide capital markets advice and invest in Sequoya to finance the development of a CBD extraction facility in Krakow, Poland. The capital raise and investment are subject to due diligence. Further details will be disclosed after definitive term sheets are executed.**

**Poland legalized the use of medical cannabis in 2017. With a population of close to 40 million and over 350,000 registered patients, the Polish market is in the early stages of adoption. Poland has implemented strict regulations for distribution of medical cannabis through pharmacies. Sequoya will market Prescriptii to Poland's 13,700 pharmacies to assist them with management of medical cannabis patient treatment and to collect and analyze medical cannabis data.**

**Under the licence agreement, Sequoya has the exclusive right to market Global Cannabis's Citizen Green Prescriptii patient-care solution to over 13,700 pharmacies in Poland. For exclusivity, Sequoya shall: i) issue Global Cannabis five million common shares of Sequoya; ii) pay Global Cannabis $100,000 by way of convertible debenture; and, iii) pay Global Cannabis a monthly fee based on the number of users. The term of the licence agreement is a one year period with an automatic renewal.**

**Global Cannabis will also purchase an additional five million shares of Sequoya in exchange for four million shares of Global Cannabis. Sequoya will grant Global Cannabis an option to purchase 10 million shares of Sequoya for $600,000 for a term of 90 days from the execution of the licence agreement. Subject to regulatory approval, Global Cannabis will own 10 million shares of Sequoya and have an option to purchase an additional 10 million shares. Sequoya now has approximately 70.31 million shares issued, such that Global Cannabis will own approximately 12.5 per cent of Sequoya and 22 per cent if it exercises the option.**

**About Sequoya Cannabis Ltd.**

**Sequoya is a Canadian and European wholesale distributor of cannabis-based products to the Polish market place and Europe in general. Sequoya is presently going to stage 2 of their business plan and preparing to manufacture CBD isolates and to become a licensed importer for medical marijuana and various derivatives for the European marketplace.**

**About Global Cannabis Applications Corp.**

 **Global Cannabis is a global leader in designing, developing, marketing and acquiring innovative data technologies for the medical cannabis industry. The Citizen Green platform is the world's first end-to-end -- from patient to regulator -- medical cannabis data solution. It uses six core technologies: mobile applications, artificial intelligence, regulatory technology, smart databases, blockchain and digital reward tokens, to qualify candidates for clinical studies. These technologies facilitate the proliferation of digital conversations by like-minded people in the medical cannabis community.**

**The above news release can be viewed under the Issuer’s profile on SEDAR (www.sedar.com) and on the Issuer’s Disclosure Page on the Canadian Securities Exchange’s website.**

1. Describe and provide details of any new products or services developed or offered. For resource companies, provide details of new drilling, exploration or production programs and acquisitions of any new properties and attach any mineral or oil and gas or other reports required under Ontario securities law.

**None to report during the month of May 2019.**

1. Describe and provide details of any products or services that were discontinued. For resource companies, provide details of any drilling, exploration or production programs that have been amended or abandoned.

**None to report during the month of May 2019.**

1. Describe any new business relationships entered into between the Issuer, the Issuer’s affiliates or third parties including contracts to supply products or services, joint venture agreements and licensing agreements, etc. State whether the relationship is with a Related Person of the Issuer and provide details of the relationship.

**Other than the above news release, none to report during the month of May 2019.**

1. Describe the expiry or termination of any contracts or agreements between the Issuer, the Issuer’s affiliates or third parties or cancellation of any financing arrangements that have been previously announced.

**None to report during the month of May 2019.**

1. Describe any acquisitions by the Issuer or dispositions of the Issuer’s assets that occurred during the preceding month. Provide details of the nature of the assets acquired or disposed of and provide details of the consideration paid or payable together with a schedule of payments if applicable, and of any valuation. State how the consideration was determined and whether the acquisition was from or the disposition was to a Related Person of the Issuer and provide details of the relationship.

**None to report during the month of May 2019.**

1. Describe the acquisition of new customers or loss of customers.

**None to report during the month of May 2019.**

1. Describe any new developments or effects on intangible products such as brand names, circulation lists, copyrights, franchises, licenses, patents, software, subscription lists and trade-marks.

**None to report during the month of May 2019.**

1. Report on any employee hirings, terminations or lay-offs with details of anticipated length of lay-offs.

**None to report during the month of May 2019.**

1. Report on any labour disputes and resolutions of those disputes, if applicable.

**None to report during the month of May 2019.**

1. Describe and provide details of legal proceedings to which the Issuer became a party, including the name of the court or agency, the date instituted, the principal parties to the proceedings, the nature of the claim, the amount claimed, if any, if the proceedings are being contested, and the present status of the proceedings.

**None to report during the month of May 2019.**

1. Provide details of any indebtedness incurred or repaid by the Issuer together with the terms of such indebtedness.

**None to report during the month of May 2019.**

1. Provide details of any securities issued and options or warrants granted.

|  |  |  |  |
| --- | --- | --- | --- |
| **Security** | **Number Issued** | **Details of Issuance** | **Use of Proceeds (1)** |
| Common shares | 100,000 | Common shares issued pursuant to the exercise of stock options. | $10,000 for working capital and general corporate purposes |
| Stock options | 1,100,000 | Stock options granted May 13, 2019 (1,025,000) and May 28, 2019 (75,000), each exercisable at $0.10 expiring five years after grant. | Not applicable |

1. *State aggregate proceeds and intended allocation of proceeds*
2. Provide details of any loans to or by Related Persons.

**None to report during the month of May 2019.**

1. Provide details of any changes in directors, officers or committee members.

**None to report during the month of May 2019.**

1. Discuss any trends which are likely to impact the Issuer including trends in the Issuer’s market(s) or political/regulatory trends.

**Trends and risks, which may impact the Issuer, are detailed in Item 17, *Risk Factors*, of the Issuer’s Form 2A – Listing Statement dated September 16, 2014.**

**THE REMAINDER OF THIS PAGE IS INTENTIONALLY LEFT BLANK.**

**Certificate of Compliance**

The undersigned hereby certifies that:

1. The undersigned is a director and/or senior officer of the Issuer and has been duly authorized by a resolution of the board of directors of the Issuer to sign this Certificate of Compliance.
2. As of the date hereof there is no material information concerning the Issuer which has not been publicly disclosed.
3. The undersigned hereby certifies to the Exchange that the Issuer is in compliance with the requirements of applicable securities legislation (as such term is defined in National Instrument 14-101) and all Exchange Requirements (as defined in CNSX Policy 1).
4. All of the information in this Form 7 Monthly Progress Report is true.

Dated June 6, 2019

 Bradley Moore
Name of Director or Senior Officer

 */s/ Bradley Moore*
Signature

Chief Executive Officer, Director
Official Capacity

|  |  |  |
| --- | --- | --- |
| Issuer DetailsName of IssuerGlobal Cannabis Applications Corp. | For Month EndApril 2019 | Date of ReportYY/MM/DD19/06/06 |
| Issuer AddressSuite 830, 1100 Melville Street Vancouver, BC V6E 4A6 | Issuer Fax No.N/A | Issuer Telephone No.(855) 269-9554 |
| Contact NameBradley Moore | Contact PositionCEO, Director | Contact Telephone No.(855) 269-9554 |
| Contact Email Addressinfo@cannappscorp.com | Web Site Addresswww.cannappscorp.com |